Sudan Virus Antibody Combination Plant Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Sudan virus (SUDV) infection lack effective antibody-based therapies, with previous attempts failing to provide protection in nonhuman primates, and there is a need for direct comparisons of plant- and mammalian-produced monoclonal antibodies for ebolavirus therapies.
Innovation Solution
Development of a therapeutically effective combination of SUDV-specific monoclonal antibodies produced using both plant and mammalian expression systems, comprising specific heavy and light chain variable regions, and their humanized variants, which are administered to patients to treat Sudan virus infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are produced using mammalian cell-based expression systems, then antibody performance and neutralizing activity are improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent changes the production platform parameter from mammalian cell-based systems to plant-based expression systems. This parameter change maintains antibody neutralizing activity while simplifying manufacturing processes, reducing costs, and eliminating animal-derived contaminants, thereby resolving the contradiction between reliability and manufacturing complexity
Solution Approach 2:
The patent creates copies of mammalian-produced monoclonal antibodies using plant expression systems. The plant-produced antibodies are engineered to replicate the same amino acid sequences and structural features as their mammalian counterparts, achieving equivalent neutralizing activity against Sudan virus through this copying approach
2Reliability
If combination monoclonal antibody therapies are developed, then protective efficacy against Sudan virus is improved, but the number of components and formulation complexity increase
Solution Approach 1:
The patent merges multiple monoclonal antibodies into a single combination therapy formulation targeting different epitopes on the Sudan virus glycoprotein. This combining approach enhances protective efficacy by targeting multiple viral components simultaneously, while the antibodies are produced using the same simplified plant-based system, preventing formulation complexity from escalating
Solution Approach 2:
The plant-based expression system serves multiple functions: it produces individual monoclonal antibodies, generates combination formulations, and provides a scalable manufacturing platform. This multi-functional approach allows the same system to handle both single and combination therapies, reducing overall formulation complexity
3Productivity
If plant-based expression systems are used for antibody production, then manufacturing scalability and cost-effectiveness are improved, but concerns about regulatory acceptance and immunogenicity arise
Solution Approach 1:
The plant-based expression system is engineered to self-regulate glycosylation patterns to match mammalian N-glycan structures. This self-service capability ensures that the antibodies produced have appropriate post-translational modifications for human therapeutic use, addressing regulatory concerns about immunogenicity while maintaining manufacturing scalability
Solution Approach 2:
The patent changes the glycosylation parameter in plant-produced antibodies to match mammalian patterns. By modifying this critical parameter, the antibodies achieve regulatory acceptance criteria for human therapeutic use while retaining the productivity advantages of plant-based systems
Data Source
AI summary
Formulations and methods of treatment for a patient infected with Sudan vims are provided. The formulation comprises a therapeutically effective combination of: (i). a first monoclonal antibody comprising a heavy chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ. ID NO: 5, and a light chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 6, therapeutically effective mutations, and humanized variants thereof, and humanized variants thereof; (ii). a second monoclonal antibody comprising a heavy chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ. ID NO: 13 and a light chain variable region comprising an amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 14, therapeutically effective mutations, and humanized variants thereof.